Biedru informācija
Dr Marta Morales Ballús
Spānija
Komanda
Dr Jaume Català Mora
Spānija
Dr Elisa Carreras
Spānija
Dr Itziar Alonso
Spānija
Dr Isabel Ayet
Spānija
Dr Ester Casas
Spānija
Optometrist Ana Díaz
Spānija
Dr Jesús Díaz
Spānija
Optometrist Enric Puigventos
Spānija
Optometrist Carles Fresno
Spānija
Dr Carmen García Vicuña
Spānija
Dr Hugo Gonzalez
Spānija
Optometrist Enrique Jimenez
Spānija
Dr Ana Llorca
Spānija
Dr Antonio Federico Martinez Monstseny
Spānija
Dr Joan Prat
Spānija
Dr Gemma Romeu
Spānija
Dr Alicia Serra
Spānija
Optometrist Simone Suh
Spānija
Dr Mariona Vidal
Spānija
Optometrist Begoña Yeste
Spānija
Dr Núria Planas
Spānija
HCP centrs
kontakts
Hospital Sant Joan de Déu, Spain
Klīniskie izmēģinājumi
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG
A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).
MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation